Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2001
10/30/2001US6310082 Benzimidazole compounds
10/30/2001US6310079 Non-steroidal antiinflammatory agents
10/30/2001US6310057 α-ketoamide multicatalytic protease inhibitors
10/30/2001US6310045 Compositions and methods for cancer immunotherapy
10/30/2001US6310039 Tumor-inhibiting conjugates of proteins and polymers consisting of a suitable carrier system and cytostatic compounds
10/30/2001US6309856 Human MAD proteins and uses thereof
10/30/2001US6309672 Anti-cancer therapy agent of arsenic hexoxide (As4O6) of a natural chemical substance and its pharmaceutical composition
10/30/2001US6309663 Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
10/30/2001CA2216160C Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
10/30/2001CA2170143C Cell death regulator
10/30/2001CA2090700C Modified antibodies with controlled clearance time
10/30/2001CA2037687C 7-(diphenylmethyl)oxy-9a-methoxymitosane and making and use thereof
10/27/2001CA2345444A1 Novel therapeutic processes and useful compositions therefor
10/25/2001WO2001083485A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives
10/25/2001WO2001079524A2 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof
10/25/2001WO2001079502A2 Vectors for gene therapy
10/25/2001WO2001079495A1 Method of inducing tumor cell apoptosis using trail/apo-2 ligand gene transfer
10/25/2001WO2001079494A1 Agonist antibodies
10/25/2001WO2001079480A1 Albumin fusion proteins
10/25/2001WO2001079479A2 Methods for selective targeting
10/25/2001WO2001079469A2 Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses
10/25/2001WO2001079468A2 Drug metabolizing enzymes
10/25/2001WO2001079444A2 Albumin fusion proteins
10/25/2001WO2001079443A2 Albumin fusion proteins
10/25/2001WO2001079442A2 Albumin fusion proteins
10/25/2001WO2001079436A2 A novel polypeptide - human cell differentiation transcription factor 10 and the polynucleotide encoding said polypeptide
10/25/2001WO2001079425A2 A novel polypeptide - human chloride channel protein 10 and the polynucleotide encoding said polypeptide
10/25/2001WO2001079302A1 A complex between folic acid and polysaccharides, its preparation method and a pharmaceutical composition comprising said complex as active component
10/25/2001WO2001079299A1 Enhancement of antibody-mediated immune responses
10/25/2001WO2001079291A2 Secreted proteins
10/25/2001WO2001079288A2 Cytokine uses; compositions; methods
10/25/2001WO2001079286A2 Compositions and methods for the therapy and diagnosis of breast cancer
10/25/2001WO2001079282A2 Molecules associated with human reproduction
10/25/2001WO2001079280A1 A novel polypeptide - human ccr4 protein 16 and the polynucleotide encoding said polypeptide
10/25/2001WO2001079271A1 Albumin fusion proteins
10/25/2001WO2001079269A2 Lipid binding protein 4
10/25/2001WO2001079259A1 Javelinization of protein antigens to heat shock proteins
10/25/2001WO2001079258A1 Albumin fusion proteins
10/25/2001WO2001079256A1 19-norbufalin derivatives, their preparation and pharmaceutical compositions containing them
10/25/2001WO2001079253A1 Extracellular matrix polynucleotides, polypeptides, and antibodies
10/25/2001WO2001079249A2 Peptide nucleic acid derivatives with a negative charge, agents and methods for producing them
10/25/2001WO2001079246A2 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
10/25/2001WO2001079216A2 Polyamide nucleic acid derivatives, agents and methods for producing them
10/25/2001WO2001079206A1 Tricyclic quinazolinediones
10/25/2001WO2001079198A1 Pyrazoles for inhibiting protein kinase
10/25/2001WO2001079197A1 ACTIVATORS FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ (PPARδ)
10/25/2001WO2001079187A2 Substituted 1,4-thiazepine and analogs and their use as activators of caspases
10/25/2001WO2001079184A1 Substituted piperazine compounds
10/25/2001WO2001079180A2 5-substituted tetralones as inhibitors of ras farnesyl transferase
10/25/2001WO2001079179A2 Dihydro-2h-naphthalene-1-one inhibitors of ras farnesyl transferase
10/25/2001WO2001079172A1 Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same
10/25/2001WO2001079164A2 N-substituted dithiocarbamates for the treatment of biological disorders
10/25/2001WO2001079158A2 Compounds for modulating cell proliferation
10/25/2001WO2001079157A1 Hydrazide and alkoxyamide angiogenesis inhibitors
10/25/2001WO2001079156A1 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001WO2001079155A2 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
10/25/2001WO2001078789A2 Poliovirus replicons encoding therapeutic agents and uses thereof
10/25/2001WO2001078784A1 Aqueous-prodrug compound comprising moiety of paclitxel or derivatives thereof, method of preparing same and pharmaceutical composition comprising same
10/25/2001WO2001078783A2 Compositions comprising natural agents for treatment of cancer
10/25/2001WO2001078772A1 Heat shock protein-based antiviral vaccines
10/25/2001WO2001078769A2 Regulation of systemic immune responses utilizing soluble cd40
10/25/2001WO2001078766A1 Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells
10/25/2001WO2001078756A2 Agent for postoperative use after the removal of bone tumours
10/25/2001WO2001078734A1 Methods of treatment
10/25/2001WO2001078733A1 Alpha,beta-unsaturated sulfones for treating proliferative disorders
10/25/2001WO2001078723A1 Compounds and methods
10/25/2001WO2001078722A1 Pharmaceutical compositions containing 5-hydroxyoxindole and use thereof
10/25/2001WO2001078720A1 Decreasing the intracellular level of beta-catenin by administering hydroxymatairesinol
10/25/2001WO2001078719A1 Halogentated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001WO2001078712A1 Substituted styryl benzylsulfones for treating proliferative disorders
10/25/2001WO2001078710A2 Paclitaxel treatment regimen for metastatic melanoma
10/25/2001WO2001078709A2 Treatment of neurodegenerative disease
10/25/2001WO2001078705A2 Compositions containing a naphthalmide and an antiproliferative agent
10/25/2001WO2001078702A2 Methods and compositions for modulating alpha adrenergic receptor activity
10/25/2001WO2001078701A2 Method and compositions for preventing hormone induced adverse effects
10/25/2001WO2001078700A2 Compositions for use in modulating immune system function comprising at least one retrinoid and at least one cytokine
10/25/2001WO2001078655A2 Methods and compositions for heat shock protein mediated immunotherapy of melanoma
10/25/2001WO2001078654A2 Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001WO2001078651A2 Method for treating neoplasmin with topoisomase i inhibitor
10/25/2001WO2001078649A2 Pharmaceutical curative compound
10/25/2001WO2001049317A9 Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen
10/25/2001WO2001049288A9 Novel compounds and compositions as protease inhibitors
10/25/2001WO2001044246A8 Bicyclic inhibitors of glycogen synthase kinase 3
10/25/2001WO2001040499A3 Methods for cell screening of compounds capable of modulating the activity of ubiquitin-ligase scf complexes and their uses
10/25/2001WO2001039786A3 New uses of suppressive macrophage activation factors
10/25/2001WO2001027159A3 Polypeptides for detection and elimination of ca19-9 antigen positive cells
10/25/2001WO2001027113A3 PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES
10/25/2001WO2001025238A3 Heterocyclic compounds useful as inhibitors of tyrosine kinases
10/25/2001WO2001024684A3 Methods for treatment of solid tumors and metastasis by gene therapy
10/25/2001WO2001023421A3 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
10/25/2001WO2001012790A3 Isomerase proteins
10/25/2001WO2001012663A3 Hematopoietic regulatory factors and methods of use thereof
10/25/2001WO2001000245A3 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
10/25/2001WO2000056737A9 Calanolides for inhibiting btk
10/25/2001WO2000040605A9 Compositions and methods relating to cyclic compounds that undergo nucleotide base pair-specific interactions with double-stranded nucleic acids
10/25/2001WO2000011169A3 Human cell signaling proteins (csig)
10/25/2001US20010034452 Epothilons C and D, preparation and compositions
10/25/2001US20010034447 N-(5-tert-butyl-2-methoxyphenyl)-n'-(4-(1-oxoisoindolin-5-ylox y)penyl)urea as anticarcinogenic agents
10/25/2001US20010034440 Complexing the target cell with therapeutic agent; antiproliferative agent
10/25/2001US20010034436 Polynucleotide and polypeptides, screening for antibiotic activity, Staphylococcus
1 ... 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 ... 2211